Correlation Engine 2.0
Clear Search sequence regions

  • AKT (1)
  • humans (1)
  • ligands (2)
  • mTOR (1)
  • PI3K (10)
  • protein b (1)
  • protein target (1)
  • rapamycin (1)
  • signal (1)
  • Sizes of these terms reflect their relevance to your search.

    Overexpression of the Phosphatidylinositol 3-kinase (PI3K) proteins have been observed in cancer cells. Targeting the phosphatidylinositol 3-kinase (PI3K) signaling transduction pathway by inhibition of the PI3K substrate recognition sites has been proved to be an effective approach to block cancer progression. Many PI3K inhibitors have been developed. Seven drugs have been approved by the US FDA with a mechanism of targeting the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway. In this study, we used docking tools to investigate selective binding of ligands toward four different subtypes of PI3Ks (PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ). The affinity predicted from both the Glide dock and the Movable-Type (MT)-based free energy calculations agreed well with the experimental data. The validation of our predicted methods with a large dataset of 147 ligands showed very small mean errors. We identified residues that may dictate the subtype-specific binding. Particularly, residues Asp964, Ser806, Lys890 and Thr886 of PI3Kγ might be utilized for PI3Kγ-selective inhibitor design. Residues Val828, Trp760, Glu826 and Tyr813 may be important for PI3Kδ-selective inhibitor binding. Copyright © 2023 Elsevier Inc. All rights reserved.


    Mohammad Al Hasan, Matthew Sabirianov, Grace Redwine, Kaitlin Goettsch, Stephen X Yang, Haizhen A Zhong. Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors. Journal of molecular graphics & modelling. 2023 Jun;121:108433

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36812742

    View Full Text